Status:
UNKNOWN
Ertapenem in Patients With Urosepsis
Lead Sponsor:
Prince of Songkla University
Conditions:
Patients With Urosepis and Received Ertapenem for Treatment
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Ertapenem, a broad-spectrum carbapenem antibiotic, has shown promising in vitro activity agenst ESBL-producing Enterobacteriacae. This agent was licensed in United State of America and Europe for seve...
Eligibility Criteria
Inclusion
- \>18 years of age
- Diagnosis of urosepsis
Exclusion
- They were pregnant
- Circulatory shock (defined as a systolic blood pressure of \< 90 mmHg and pour tissue perfusion)
- Documented hypersensitivity to carbapenems
- Estimated creatinine clearance (CLcr) (determined by the Crockcroft-Goult method) of \< 30 mL/min
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT03859362
Start Date
January 1 2017
End Date
December 31 2021
Last Update
March 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University
Hat Yai, Changwat Songkhla, Thailand, 90110